43 Patents
- US123184072025Peptides Displayed by HLA for Use in Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US122905302025Peptides Displayed by HLA for Use in Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US122854432025Peptides Displayed by HLA for Use Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US122747162025Peptides Displayed by HLA for Use Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US122572692025Peptides Displayed by HLA for Use in Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US122460392025Peptides Displayed by HLA for Use in Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US122275562025Immunotherapy with B*08 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US122028782025Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US121955062025Immunotherapy with A*01 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US121955162025Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US121629172024B*44 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US120844862024Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US120763792024A*03 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US120654712024B*44 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US120603992024Immunotherapy with A*01 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - 0 cites
- US119577162024Peptides Displayed by HLA for Use in Immunotherapy Against Different Types of Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US119511322024Peptides and Combination of Peptides of Non-canonical Origin for Use in Immunotherapy Against Different Types of Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US119524092024Amidated Peptides and Their Deamidated Counterparts Displayed by Non-hla-a*02 for Use in Immunotherapy Against Different Types of Cancers Preliminary Class
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US119458502024B*44 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US119186072024Peptides and Combination of Peptides of Non-canonical Origin for Use in Immunotherapy Against Different Types of Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US119040032024Amidated Peptides and Their Deamidated Counterparts Displayed by HLA-A*02 for Use in Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US118914272024Amidated Peptides and Their Deamidated Counterparts Displayed by Non-hla-a*02 for Use in Immunotherapy Against Different Types of Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US118722702024A*03 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US118331932023A*03 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US118331952023Amidated Peptides and Their Deamidated Counterparts Displayed by HLA-A*02 for Use in Immunotherapy Against Different Types of Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US118012642023Peptides and Combination of Peptides of Non-canonical Origin for Use in Immunotherapy Against Different Types of Cancers
Immatics Biotechnologies GmbH
0 cites - US117796052023Immunotherapy with B*08 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
Immatics Biotechnologies GmbH
0 cites - US117796062023Peptides and Combination of Peptides of Non-canonical Origin for Use in Immunotherapy Against Different Types of Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US117320212023Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - 0 cites
- US116800892023B*44 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US116676852023B*44 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US116552802023Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US116552812023Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US116291772023B*44 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US116033972023Immunotherapy with B*07 Restricted Peptides and Combination of Peptides Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US115769552023A*03 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US115595502023Peptides and Combination of Peptides for Use in Immunotherapy Against Leukemias and Other Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US115604052023Peptides and Combination Thereof for Use in the Immunotherapy Against Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US115541642023A*03 Restricted Peptides for Use in Immunotherapy Against Cancers and Related Methods
IMMATICS BIOTECHNOLOGIES GmbH
0 cites - US115423032023Peptides and Combination Thereof for Use in the Immunotherapy Against Cancers
IMMATICS BIOTECHNOLOGIES GmbH
0 cites